21 December 2021
Abingdon Health plc
("Abingdon" or "the Company")
Director/PDMR Dealings
York, U.K. 21 December 2021: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, confirms the participation of certain Directors in the Second Placing, pursuant to the Fundraising announced on 1 December 2021.
Director Participation in the Placing
| Participating Director | Number of Existing Ordinary Shares | Number of Placing Shares subscribed for in the Placing | Number of Ordinary Shares held following Second Admission | Percentage of Enlarged Share Capital on Admission |
| Dr Christopher Hand | 11,228,868 | 999,599 | 12,228,467 | 10.0% |
| Chris Yates | 6,513,844 | 1,000,000 | 7,513,844 | 6.2% |
Concert Party Interests
Following completion of the Fundraising, the interests of the Concert Party have reduced to 35.8 per cent. of the Company's total voting rights.
Capitalised terms used in this announcement shall have the same meanings as defined in the Circular sent to Shareholders and available to view on the Company's website, as published by the Company on 2 December 2021.
Enquiries:
| Abingdon Health plc | |||
| Chris Yates, Chief Executive Officer | Via Walbrook PR | ||
| Melanie Ross, Chief Financial Officer | | ||
| Christopher Hand, Non-Executive Chairman | | ||
| | | ||
| Singer Capital Markets (Sole Broker and Nominated Adviser) | Tel: +44 (0)20 7496 3000 | ||
| Shaun Dobson, Peter Steel, Alex Bond (Corporate Finance) | | ||
| Tom Salvesen (Corporate Broking) | | ||
| | | ||
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com | ||
| Paul McManus / Phillip Marriage | Mob: +44 (0)7980 541 893 / +44 (0)77867 984 082 | ||
| Alice Woodings | Mob: +44 (0)7407 804 654 | ||
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York, England.
For more information visit: www.abingdonhealth.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
| a)
| Name
| Chris Yates | ||||
| 2
| Reason for the notification | |||||
| a)
| Position/status | Chief Executive Officer | ||||
| b)
| Initial notification /Amendment | Initial Notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a)
| Name | Abingdon Health plc | ||||
| b)
| LEI
| 213800XFI4WV3FBILO20 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
| a)
| Description of the financial instrument, type of instrument | Ordinary Shares of 0.025 pence each | ||||
| | | |||||
| Identification code | GB00BLF79J41 | |||||
| | | |||||
| b)
| Nature of the transaction
| Purchase of Ordinary Shares
| ||||
| c)
| Price(s) and volume(s) | | | | | |
| | | Price(s) | Volume(s) | | ||
| | | 25.00 pence | 1,000,000 | | ||
| | | | | | ||
| d)
| Aggregated information | | N/A - Single transaction | | | |
| | | |||||
| e)
| Date of the transaction | 21 December 2021 | ||||
| f)
| Place of the transaction | Outside a trading venue
| ||||
| | | | | | | |
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
| a)
| Name
| Dr Christopher Hand | ||||
| 2
| Reason for the notification | |||||
| a)
| Position/status | Chairman | ||||
| b)
| Initial notification /Amendment | Initial Notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a)
| Name | Abingdon Health plc | ||||
| b)
| LEI
| 213800XFI4WV3FBILO20 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
| a)
| Description of the financial instrument, type of instrument | Ordinary Shares of 0.025 pence each | ||||
| | | |||||
| Identification code | GB00BLF79J41 | |||||
| | | |||||
| b)
| Nature of the transaction
| Purchase of Ordinary Shares
| ||||
| c)
| Price(s) and volume(s) | | | | | |
| | | Price(s) | Volume(s) | | ||
| | | 25.00 pence | 999,599 | | ||
| | | | | | ||
| d)
| Aggregated information | | N/A - Single transaction | | | |
| | | |||||
| e)
| Date of the transaction | 21 December 2021 | ||||
| f)
| Place of the transaction | Outside a trading venue
| ||||
| | | | | | | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
